Plain English Summary
Study website
Contact information
Type
Scientific
Contact name
Miss Ann Marie Hynes
ORCID ID
Contact details
Clinical Trials Unit
Faculty of Medical Sciences
Newcastle University
1 – 4 Claremont Terrace
Newcastle upon Tyne
NE2 4AE
United Kingdom
+44 (0)191 208 7647
Ann.hynes@newcastle.ac.uk
Additional identifiers
EudraCT/CTIS number
IRAS number
ClinicalTrials.gov number
Protocol/serial number
17090
Study information
Scientific title
SURAB study: a randomised study comparing ABlation with active SURveillance, in the management of incidentally diagnosed small renal tumours: a feasibility study
Acronym
SURAB
Study hypothesis
The aim of this study is to establish whether a future definitive trial comparing active surveillance with ablative treatment for small kidney cancer is feasible. There is also a pre-pilot qualitative component to the study which will inform trial design.
More details can be found at http://www.nets.nihr.ac.uk/projects/hta/1110701
Protocol can be found at http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0018/115560/PRO-11-107-01.pdf
Ethics approval(s)
14/NE/0155; First MREC approval date 26/07/2014
Study design
Randomised; Interventional; Design type: Process of Care, Treatment
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Study setting(s)
Hospital
Study type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Topic: Cancer; Subtopic: Renal Cancer; Disease: Kidney
Intervention
Ablation, Currently, centres have tended to develop expertise in either cryotherapy or radiofrequency ablation; centres will therefore offer only one form of ablation (the one in which they have expertise). There will also be an opportunity for departments which offer microwave ablation to participate in the trial.; Active Surveillance, Participants will be monitored for the duration of the trial; Follow Up Length: 6 month(s); Study Entry : Single Randomisation only
Intervention type
Other
Primary outcome measure
The aim is to establish whether a future definitive trial comparing active surveillance with ablative treatment for small kidney cancer is feasible. This will be assessed quantitatively in terms of recruitment and retention rates and qualitatively in terms of the patients' experiences and understanding of the randomisation process and treatment options. Partition of reasons for loss to follow up, together with clinical data, will allow us to project likely retention at 5 years.
Secondary outcome measures
All secondary outcomes will be rehearsed during the pilot trial with a view to refining the choice of outcomes for the main trial, based on data yield and quality.
Outcome data collection in the pilot feasibility trial will be timed to coincide with routine clinical assessments and will collected from patients at 4,7 months post randomisation (3, 6 months post treatment).
The following secondary outcome questionnaires will be completed at baseline (within 14 days before randomisation) and at 3 and 6 months post treatment:
1. A general health questionnaire (SF-36)
2. Cancer specific health status and quality of life (FACT-G)
3. Anxiety and depression (STAI)
We have also developed and plan to test health economics data collection tools in the form of a participant costs questionnaire (PCQ). The PCQ has two parts: Part A to be administered at 3 month and 6 month and Part B at 6 month only.
Overall study start date
01/10/2014
Overall study end date
31/10/2016
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Adult diagnosed with renal cancer < 4 cm (confirmation by radiology* or by biopsy)
2. ASA physical status classification system grade 1 or 2
3. Age =18 years of age
4. CT/MRI abdomen/chest with no evidence of metastases
5. Patient has provided written informed consent prior to any study specific procedures
*Radiological confirmation requires noting an enhancing renal mass of >20 Hounsfield units.
Participant type(s)
Patient
Age group
Adult
Lower age limit
18 Years
Sex
Both
Target number of participants
Planned Sample Size: 60; UK Sample Size: 60
Participant exclusion criteria
Current exclusion criteria as of 09/03/2015:
Patients the clinician does not feel would be suitable for the trial (e.g., due to concomitant disease)
1. Multiple small renal cancers in one kidney
2. Coagulopathy that cannot be corrected
3. Previous participation in this study
4. Inability to give informed consent; carer/proxy consent will not be allowed in this study
Previous exclusion criteria:
Patients the clinician does not feel would be suitable for the trial (e.g., due to concomitant disease)
1. Fuhrman grade 3 / 4
2. Multiple small renal cancers in one kidney
3. Coagulopathy that cannot be corrected
4. Previous participation in this study
5. Inability to give informed consent; carer/proxy consent will not be allowed in this study
Recruitment start date
01/04/2015
Recruitment end date
29/02/2016
Locations
Countries of recruitment
England, United Kingdom
Study participating centre
For full details on participating centres please contact:
Clinical Trials Unit
Faculty of Medical Sciences
Newcastle University
1 – 4 Claremont Terrace
Newcastle upon Tyne
NE2 4AE
United Kingdom
Sponsor information
Organisation
Newcastle upon Tyne Hospitals NHS Foundation (UK)
Sponsor details
CRO – Level 6; Leazes Wing
Royal Victoria Infirmary
Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
England
United Kingdom
Sponsor type
Hospital/treatment centre
Website
ROR
Funders
Funder type
Government
Funder name
Health Technology Assessment Programme
Alternative name(s)
NIHR Health Technology Assessment Programme, HTA
Funding Body Type
government organisation
Funding Body Subtype
National government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Our exact publication policy is not yet known although conference presentations and a peer-reviewed journal article/s are highly likely. We do not plan to inform patients of results on an individual basis; however, we will aim to disseminate findings to the public (and hence patients) through a range of mechanisms (peer review journal, conference presentations etc).
Intention to publish date
Individual participant data (IPD) sharing plan
IPD sharing plan summary
Other
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/12/2017 | Yes | No | |
Plain English results | 09/03/2020 | No | Yes | ||
HRA research summary | 28/06/2023 | No | No |